Glenmark Pharmaceuticals Ltd was given a notice by the Drug Controller General of India (DCGI) on overpricing and false claims of its generic version of favipiravir, FabiFlu, according to local media reports, sending the company’s shares down as much as 5.8% on Monday.
The drug regulator said that "the cost proposed by Glenmark (for FabiFlu) is definitely not in the interest of the poor, lower middle class and middle class people of India”, in the letter to the newspaper Mint on Sunday.
Glenmark and the DCGI were not immediately available to respond to Reuters' requests for comment.
The Mumbai-based company reduced the price of FabiFlu to ₹75 ($1.00) per tablet last week for restricted emergency use in patients with mild-to-moderate COVID-19 symptoms in India.
The DCGI also questioned Glenmark's claims of FabiFlu’s effectiveness in co-morbid conditions like hypertension and diabetes, Mint said.
European shares traded lower earlier on Thursday after underwhelming earnings reports dampened a U.S. Fed vow to continue rolling out stimulus plans in a bid to soften the economic blow of the COVID-19 pandemic. The pan-European STOXX lost ...
European stocks traded slightly higher on Tuesday ahead of a U.S. decision to roll out additional stimulus plans despite the underwhelming quarterly earnings reports from the luxury goods market. The pan-European STOXX index inched higher ...
Samsung Electronics’ shares joined TSMC, its competitor, as both extended gains on Tuesday. This was mainly from upbeat expectations that Intel Corp’s plan of outsourcing more chip producers would favor the chipmakers. Shares of ...
Financial markets saw record heights earlier on Friday, with the Euro continuing its 21-month gain streak and gold prices hitting its highest level amid a weakened Dollar. The Euro soared above the Dollar by 1.7%, trading at $1.1616 for the ...
Asian shares fell on Thursday as the U.S.-China tensions overshadowed hopes for more economic stimulus after Washington ordered the closure of Beijing’s consulate in Houston amid spying allegations. China called the order an “unprecedented ...